Identification of Subgroups of Schizophrenia Patients With Changes in Either Immune or Growth Factor and Hormonal Pathways
Open Access
- 9 August 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 40 (4), 787-795
- https://doi.org/10.1093/schbul/sbt105
Abstract
Schizophrenia is a heterogeneous disorder normally diagnosed using the Diagnostic and Statistical Manual of Mental Disorders criteria. However, these criteria do not necessarily reflect differences in underlying molecular abnormalities of the disorder. Here, we have used multiplexed immunoassay analyses to measure immune molecules, growth factors, and hormones important to schizophrenia in acutely ill antipsychotic-naive patients (n = 180) and matched controls (n = 398). We found that using the resulting molecular profiles, we were capable of separating schizophrenia patients into 2 significantly distinct subgroups with predominant molecular abnormalities in either immune molecules or growth factors and hormones. These molecular profiles were tested using an independent cohort, and this showed the same separation into 2 subgroups. This suggests that distinct abnormalities occur in specific molecular pathways in schizophrenia patients. This may be of relevance for intervention studies that specifically target particular molecular mechanisms and could be a first step to further define the complex schizophrenia syndrome based on molecular profiles.Keywords
This publication has 41 references indexed in Scilit:
- Serum and gene expression profile of cytokines in first-episode psychosisBrain, Behavior, and Immunity, 2013
- Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer diseaseNeurobiology of Aging, 2011
- Identification of a biological signature for schizophrenia in serumMolecular Psychiatry, 2011
- The environment and susceptibility to schizophreniaProgress in Neurobiology, 2011
- Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control CollectionsPLOS ONE, 2010
- PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's DiseaseNeurotherapeutics, 2008
- Major Depressive DisorderThe New England Journal of Medicine, 2008
- Deconstructing Schizophrenia: An Overview of the Use of Endophenotypes in Order to Understand a Complex DisorderSchizophrenia Bulletin, 2006
- Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietinMolecular Psychiatry, 2006
- Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: Potential signaling mechanismsJournal of Neuroscience Research, 2006